300 related articles for article (PubMed ID: 34597899)
1. A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual dysphoric disorder.
Bäckström T; Ekberg K; Hirschberg AL; Bixo M; Epperson CN; Briggs P; Panay N; O'Brien S
Psychoneuroendocrinology; 2021 Nov; 133():105426. PubMed ID: 34597899
[TBL] [Abstract][Full Text] [Related]
2. Treatment of premenstrual dysphoric disorder with the GABA
Bixo M; Ekberg K; Poromaa IS; Hirschberg AL; Jonasson AF; Andréen L; Timby E; Wulff M; Ehrenborg A; Bäckström T
Psychoneuroendocrinology; 2017 Jun; 80():46-55. PubMed ID: 28319848
[TBL] [Abstract][Full Text] [Related]
3. Effects of GABA active steroids in the female brain with a focus on the premenstrual dysphoric disorder.
Bixo M; Johansson M; Timby E; Michalski L; Bäckström T
J Neuroendocrinol; 2018 Feb; 30(2):. PubMed ID: 29072794
[TBL] [Abstract][Full Text] [Related]
4. Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial.
Yonkers KA; Kornstein SG; Gueorguieva R; Merry B; Van Steenburgh K; Altemus M
JAMA Psychiatry; 2015 Oct; 72(10):1037-44. PubMed ID: 26351969
[TBL] [Abstract][Full Text] [Related]
5. Ulipristal Acetate for Treatment of Premenstrual Dysphoric Disorder: A Proof-of-Concept Randomized Controlled Trial.
Comasco E; Kopp Kallner H; Bixo M; Hirschberg AL; Nyback S; de Grauw H; Epperson CN; Sundström-Poromaa I
Am J Psychiatry; 2021 Mar; 178(3):256-265. PubMed ID: 33297719
[TBL] [Abstract][Full Text] [Related]
6. 5α-Reductase Inhibition Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and Mitigates Symptoms in Women with Premenstrual Dysphoric Disorder.
Martinez PE; Rubinow DR; Nieman LK; Koziol DE; Morrow AL; Schiller CE; Cintron D; Thompson KD; Khine KK; Schmidt PJ
Neuropsychopharmacology; 2016 Mar; 41(4):1093-102. PubMed ID: 26272051
[TBL] [Abstract][Full Text] [Related]
7. GABAergic neuroactive steroid response to sertraline in premenstrual dysphoric disorder.
Miller KN; Standeven L; Morrow AL; Payne JL; Epperson CN; Hantsoo L
Psychoneuroendocrinology; 2024 Feb; 160():106684. PubMed ID: 38091917
[TBL] [Abstract][Full Text] [Related]
8. Women with premenstrual dysphoric disorder have altered sensitivity to allopregnanolone over the menstrual cycle compared to controls-a pilot study.
Timby E; Bäckström T; Nyberg S; Stenlund H; Wihlbäck AN; Bixo M
Psychopharmacology (Berl); 2016 Jun; 233(11):2109-2117. PubMed ID: 26960697
[TBL] [Abstract][Full Text] [Related]
9. A lecithin phosphatidylserine and phosphatidic acid complex (PAS) reduces symptoms of the premenstrual syndrome (PMS): Results of a randomized, placebo-controlled, double-blind clinical trial.
Schmidt K; Weber N; Steiner M; Meyer N; Dubberke A; Rutenberg D; Hellhammer J
Clin Nutr ESPEN; 2018 Apr; 24():22-30. PubMed ID: 29576358
[TBL] [Abstract][Full Text] [Related]
10. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial.
Miner C; Brown E; McCray S; Gonzales J; Wohlreich M
Clin Ther; 2002 Mar; 24(3):417-33. PubMed ID: 11952025
[TBL] [Abstract][Full Text] [Related]
11. Double-blind, placebo-controlled pilot study of adjunctive quetiapine SR in the treatment of PMS/PMDD.
Jackson C; Pearson B; Girdler S; Johnson J; Hamer RM; Killenberg S; Meltzer-Brody S
Hum Psychopharmacol; 2015 Nov; 30(6):425-34. PubMed ID: 26193781
[TBL] [Abstract][Full Text] [Related]
12. [Premenstrual dysphoric disorder (PMDD): Drug and psychotherapeutique management, a literature review].
Marais-Thomas H; Chapelle F; de Vaux-Boitouzet V; Bouvet C
Encephale; 2024 Apr; 50(2):211-232. PubMed ID: 37821319
[TBL] [Abstract][Full Text] [Related]
13. GABA-ergic Modulators: New Therapeutic Approaches to Premenstrual Dysphoric Disorder.
Sikes-Keilp C; Rubinow DR
CNS Drugs; 2023 Aug; 37(8):679-693. PubMed ID: 37542704
[TBL] [Abstract][Full Text] [Related]
14. Allopregnanolone and mood disorders.
Bäckström T; Bixo M; Johansson M; Nyberg S; Ossewaarde L; Ragagnin G; Savic I; Strömberg J; Timby E; van Broekhoven F; van Wingen G
Prog Neurobiol; 2014 Feb; 113():88-94. PubMed ID: 23978486
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 µg in the treatment of premenstrual dysphoric disorder: a randomized, double blind placebo-controlled study].
Fu Y; Mi W; Li L; Zhang H; Wang J; Cheng W; Sun L; Li L; Xie S; Zhang J
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):506-9. PubMed ID: 25327732
[TBL] [Abstract][Full Text] [Related]
16. GABAA Receptor-Modulating Steroids in Relation to Women's Behavioral Health.
Bäckström T; Bixo M; Strömberg J
Curr Psychiatry Rep; 2015 Nov; 17(11):92. PubMed ID: 26396092
[TBL] [Abstract][Full Text] [Related]
17. Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled trial in Canadian women.
Steiner M; Ravindran AV; LeMelledo JM; Carter D; Huang JO; Anonychuk AM; Simpson SD
J Clin Psychiatry; 2008 Jun; 69(6):991-8. PubMed ID: 18517289
[TBL] [Abstract][Full Text] [Related]
18. Positive GABA
Bäckström T; Das R; Bixo M
J Neuroendocrinol; 2022 Feb; 34(2):e13013. PubMed ID: 34337790
[TBL] [Abstract][Full Text] [Related]
19. Brain reactivity during aggressive response in women with premenstrual dysphoric disorder treated with a selective progesterone receptor modulator.
Kaltsouni E; Fisher PM; Dubol M; Hustad S; Lanzenberger R; Frokjaer VG; Wikström J; Comasco E; Sundström-Poromaa I
Neuropsychopharmacology; 2021 Jul; 46(8):1460-1467. PubMed ID: 33927343
[TBL] [Abstract][Full Text] [Related]
20. Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder.
Girdler SS; Straneva PA; Light KC; Pedersen CA; Morrow AL
Biol Psychiatry; 2001 May; 49(9):788-97. PubMed ID: 11331087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
